For CiPA, iPSC-CMs expressing a mature ventricular phenotype are required. At Metrion Biosciences we have focused on electrophysiological profiling of Axol Human iPSC-Derived Ventricular Cardiomyocytes (hiPSC-vCMs) by evaluating their biophysical and pharmacological characteristics.